Idiopathic pulmonary fibrosis (IPF) is a debilitating fibrotic lung disease of unknown origin and pathogenesis with a steady increase in both incidence and mortality in recent years.¹ Despite encouraging efficacy data for pirfenidone and nintedanib,^2,3 neither of these compounds has been tested prospectively in the context of IPF coexisting with lung cancer, a frequent comorbid condition of IPF.⁴ Indeed, epidemiological evidence suggests that up to 22% of patients with IPF develop lung cancer, with a risk nearly five times as high as that of the general population.

中文翻译：

---

IPF和肺癌患者：诊断和治疗

特发性肺纤维化（IPF）是一种致残性衰弱的纤维化性肺病，其来源和发病机制不明，近年来发病率和死亡率均呈稳定增长趋势。^[1]尽管有令人鼓舞的吡非尼酮和尼达尼布的疗效数据，[ ^2,3]在IPF与肺癌（一种常见的IPF合并症）并存的情况下，未对这两种化合物进行过前瞻性测试。⁴确实，流行病学证据表明，高达22％的IPF患者患肺癌，其风险几乎是普通人群的五倍。